The bronchitis randomized on NAC cost-utility study (BRONCUS): Hypothesis and design

European Respiratory Journal

Volumn 17, Issue 3, 2001, Pages 329-336

  Decramer, M ^a   Dekhuijzen, P N R ^a   Trooster, T ^a   van Herwaarden, C ^a   Rutten van Molken M ^a   van Schayck, C P O ^a   Olivieri, D ^a   Lankhorst, I ^a   Ardia, A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

COPD; Cost utility; Decline in FEV1; N acetylcysteine; Oxidative stress; Quality of life

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BRONCHODILATING AGENT; PLACEBO; SALBUTAMOL; STEROID;

ADULT; AGED; AIRWAY OBSTRUCTION; ANTIOXIDANT ACTIVITY; ARTICLE; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST UTILITY ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EUROPE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OXIDATIVE STRESS; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SAMPLE; SMOKING; TREATMENT OUTCOME;

ACETYLCYSTEINE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; EXPECTORANTS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; FUNCTIONAL RESIDUAL CAPACITY; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; SPIROMETRY; VITAL CAPACITY;

EID: 0034961209     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.01.17303290     Document Type: Article

References (29)

1. Optimal assessment and management of COPD
2. Inflammation in COPD
3. Chronic Obstructive Pulmonary Disease
4. Novel approaches and targets for the treatment of COPD
5. Long-term treatment with inhaled budesonide in persons with mild COPD who continue smoking
6. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
7. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
8. 1. The lung health study
9. Moderately severe chronic airflow obstruction: Can steroids slow down obstruction?
10. Survival of patients with COPD receiving long-term domiciliary oxygen therapy
11. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: Report of a trial organised by the Swedish Society for Pulmonary diseases
12. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study
13. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis
14. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction
15. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials
16. The effects of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review
17. Oxidative stress in COPD
18. Oxidants and antioxidants as therapeutic targets in COPD
19. Measuring individual annual decline in lung function: The impact of measurement frequency and precision
20. Standardized lung function testing
21. Spirometry in the Lung Health Study II: Determinants of short-term intraindividual varaibility
22. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire
23. Influence of demographic and disease related factors on the degree of distress associated with symptoms and restriction on daily diving due to asthma in six countries
24. EuroQoL: The current state of the play
25. Modeling valuations for EuroQol health states
26. The friction cost method for measuring indirect costs of disease
27. Active detection of chronic obstructive pulmonary disease and asthma in the general population
28. 1 measurements in emphysematous patients and normal subjects
29. Time course and recovery of exacerbations in patients with obstructive pulmonary disease